Eli Lilly’s Depression Drug May Cut Chronic Low Back Pain

Washington D.C. (AHN) – Eli Lilly and Co.’s Cymbalta depression treatment significantly reduced back pain in comparison with a placebo, new studies suggest. The drug is prescribed to treat depression, generalized anxiety disorder, diabetic nerve pain, and fibromyalgia.

The pharmaceutical company carried out a study on 236 adults with chronic low back pain who weren’t depressed. They took Cymbalta or a placebo drug daily for 13 weeks. The study found that 31 per cent of patients receiving the treatment experienced a 50 percent reduction in pain, compared with 19 percent of individuals who were in the placebo group.

Researchers said that a 60-120 milligram dose of Cymbalta produced the desired effects, a 60 -120 milligram. However, a large number of patients from the medicine group discontinued use due to adverse events, the most common of which were nausea, dry mouth, fatigue, diarrhea, excessive sweating, dizziness and constipation.

Indianapolis-based Lilly filed an application in May with the Food and Drug Administration to allow Cymbalta to be prescribed for managing chronic pain. Both studies were funded by the company.

The study was presented in Madrid at the 12th Congress of the European Federation of the Neurological Sciences.


Got something to say?

You must be logged in to post a comment.